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SUMMARY
The effects of lisuride and of the R(-)- and S(+)-enantiomers of apomorphine were
examined on 3,4-dihydroxyphenylalanine (DOPA) production by striatal synaptosomes
and by crude, soluble striatal tyrosine hydroxylase. Due to their catechol structure, the
enantiomers were almost equally effective in blocking soluble tyrosine hydroxylase (EC
1.14.16.2) (IC50 = 470 and 890 nM for R(-)- and S(+)-apomorphine, respectively),
provided incubations were performed at pH 7.2 with 1 mM tetrahydrobiopterin as cofactor.
The enantiomers were similarly effective in blocking synaptosomal DOPA production
(IC50 = 410 and 970 nM for R(-)- and S(+)-apomorphine, respectively). As S(+)-
apomorphine but not R(-)-apomorphine is considered to be a dopamine antagonist, these
results support the assumption that the block of synaptosomal DOPA production by both
apomorphine enantiomers is due to a direct inhibition of tyrosine hydroxylase. Lisuride
at high concentrations (10-100 M) blocked DOPA production in striatal synaptosomes;
simultaneously, intrasynaptosomal dopamine was depleted. These data support the
assumption that lisuride inhibits DOPA production indirectly, similar to reserpine. In
accordance with this assumption, lisuride was without effect on DOPA production in
dopamine-depleted synaptosomes. These results demonstrate that inhibition of synap-
tosomal DOPA production by at least some dopamine agonists may be explained by
direct inhibitory effects on tyrosine hydroxylase.
INTRODUCTION
The regulation of DA1 biosynthesis in dopaminergic
nerve terminals is unclear. Most authors agree that ex-
traneuronal DA (or other dopaminergic agonists) influ-
ences TH via presynaptic autoreceptors, as was originally
suggested by Carisson and Roth and their associates (1-
3). In particular, the DA agonist, R(-)-apomorphine, is
remarkably effective in blocking DOPA production in
striatal slices and synaptosomes; these findings support
the existence of DA receptors on the nerve terminal
which modulate DA synthesis (4, 5).
Studies on the regulation of TH in catechol-synthesiz-
ing clonal cell lines showed that R(-)-apomorphine
blocked DOPA production in these systems as effectively
This work was in part supported by a grant of the Bundesministe-
rium f#{252}rForschung und Technologie, D-5300 Bonn. Parts ofthe results
were reported at the International Congress of Pharmacology, IUPHAR
Satellite Symposium, Dopamine 84, Southampton, England, August 5-
9, 1984.
1 The abbreviations used are: DA, dopamine; TH, tyrosine hydrox-
ylase (EC 1.14.16.2); DOPA, 3,4-dihydroxyphenylaline; LHM, lisuride
hydrogen maleate; DOPAC, 3,4-dihydroxyphenylacetic acid; NSD 1055,
4-bromo-3-hydroxybenzyloxyamine dihydrogen phosphate; BH4, (6-R,
S)-L-erythro-5,6,7,8-tetrahydrobiopterin.
as in striatal slices and synaptosomes, but a DA receptor-
mediated mechanism could not be demonstrated in these
cell clones (6, 7). Reexamination of the effect of R(-)-
apomorphine on striatal TH enzyme preparations re-
vealed that R(-)-apomorphine-apparently due to its
catechol structure-is a very effective direct blocker of
TH, if physiological test conditions are used (8).
Apomorphine exists both in R(-)- and S(+)-enantiom-
eric forms. S(+)-Apomorphine, which contains a cate-
chol moiety as does the R(-)-form, was shown to be a
DA receptor antagonist in behavioral and biochemical
assays (9, 10). Comparison of the effects of both enanti-
omers on the activity of soluble TH and DOPA produc-
tion in striatal synaptosomes should, therefore, enable
one to distinguish an autoreceptor-mediated effect on
TH from a direct one.
Tissari et al. (11) recently reported that the ergoline
derivative, LHM, can block DOPA production in striatal
synaptosomes, but only at high concentrations. We ob-
served that LHM blocks DOPA production in the pheo-
chromocytoma cell clone PC-12 by depletion of DA from
its vesicular stores into the cytoplasm.2 Therefore, we
2 M. Br#{228}utigam, B. Kittner, and G. Laschinski, unpublished obser-
vation.
0026-895X/85/060515-06$02.00/0
Copyright © 1985 by The American Society for Pharmacology
and Experimental Therapeutics.
All rights of reproduction in any form reserved.
have reinvestigated LHM-induced inhibition of synap- SD is given in the figures. The IC values were determined by at least
tosomal DOPA production, monitoring the synaptosomal
DA and DOPAC content.
12 determinations, using at least four different concentrations.
Materials. R(-)-Apomorphine was obtained from Sigma Chemie
(Taufkirchen, FRG); S(+)-apomorphine was obtained from Research
MATERIALS AND METHODS Biochemicals Inc. (Wayland, MA). Both compounds were dissolved in
0.9% NaC1 containing 0.1% Na2S2O5. LHM was a gift of Dr. W. Kehr
DOPA production in striatal synaptosomes. Male Wistar rats (150- (Schering AG, Berlin, FRG). NSD 1055 was obtained from Smith &
250 g) were obtained from Winkelmann (Borchen, FRG). The striatum Nephew Research Ltd. (Harlow, Essex, U.K.).
was dissected after decapitation; the crude synaptosomal fraction (P2) BH4 was from Dr. B. Schircks Laboratorien (lona, Switzerland).
was prepared as described by Kapatos and Zigmond (12). The synap-
tosomes were suspended in 500 zl of sodium phosphate buffer, pH 7.4
(10 mM)/pair of striate. The buffer contained 122 mM NaC1, 0.9 mM
BH4 solutions always contained 10 mM dithioerythritol. Reserpine was
from Fluka AG (Buchs, Switzerland). Reserpine was dissolved in glacial
acetic acid at 128 mg/mI; dilutions were carried out in 0.9% NaC1. L-
CaCl2, 1.2 mM MgSO4, 4.7 mM KC1, 1.2 mM KH2PO4, 1.2 mM ascorbic [2,6-3H]Tyrosine (specific activity 41 Ci/mmol) was obtained from
acid, and 12 mM glucose. Amersham-Buchler (Braunschweig, FRG).
Measurement of DOPA production after blockade of aromatic L-amino
acid decarboxylase. The assay was performed in a total volume of 500 RESULTS
Ml ofthe above buffer containing 100 Ml ofthe synaptosomal suspension- . .
(corresponding to about 1 mg of protein), tyrosine (100 SM), and drugs
or solvents as indicated. The experiments were started by addition of
NSD 1055 to a final concentration of 100 tiM. Incubations were carried
out at 37’ and were usually stopped after 20 mm by addition of
. . .
Our method to estimate DOPA production in striatal
.
synaptosomes allows the simultaneous assessment of
synaptosomal DA and DOPAC contents. The formation
of DOPA was linear over at least 20 mm (Fig. 1A);
perchloric acid (final concentration 0.4 M). The pH was checked regu- therefore, this time interval was used to test the effects
larly and found to be between 7.0 and 7.3. Synaptosomes were sonicated of various drugs on synaptosomal DOPA production.
in the incubation buffer, centrifuged at 10,000 x g for 10 mm, and the
supernatant was assayed for DOPA, DA, and DOPAC. Protein was
determined according to the method of Lowry et al. (13).
Measurement of [3Hj catechol production. In order to validate the 60
results obtained by determining DOPA production after inhibition of
the aromatic L-amino acid decarboxylase, synaptosomal [3H]catechol
production was measured as described by Iversen et al. (18). Before
each experiment, L-[2,6-3H] tyrosine was purified from catechol im-
40
purities on aluminum oxide. The assay conditions were as described
above (without NSD 1055); after preincubation for 10 mm at 37’, the
experiments were started by adding 0.25 iCi of L-[2,6-3Hjtyrosine (per 20
test tube) diluted in nonradioactive L-tyrosine (final concentration, 5
LM). Incubation was terminated after 10 mm by the addition of per-
chloric acid as described above. Labeled catechols were isolated from
unreacted L-[2,6-3H]tyrosine by adsorption to aluminum oxide and 0      .
quantified by liquid scintillation spectrometry. Typical blank and con- 0 5 10 15 20 25 30 t (mm)
trol values were 400 and 4000 dpm/assay tube, respectively. Absolute
synaptosomal catechol production was calculated under the assumption
that the intrasynaptosomal radioactive concentration of L-[2,6-3H]
tyrosine corresponds to its concentration in the incubation buffer
without correction for recovery of [3H]catechols over aluminum oxide.
Activity of striatal TH. Preparation of crude soluble striatal TH and
assay conditions were as recently described (8). Tests reported in this
paper were performed by 5 mi Tris-HC1, pH 7.2, containing 30 zM
100
. a  I
  I I
  50 j B
 E  -j-
.2  ‘    ‘
tyrosine and 1 mM BH4. Incubation time was 30 mm.
DA-depleted synaptosomes. To analyze the effect of LHM, striatal
synaptosomes were prepared as described above and divided into two 150
fractions. One fraction was incubated with 10 jM reserpine, and the .
other one was incubated with the appropriate control solution for 20
mm at 37’. This incubation time was sufficient to deplete DA from the s ioo
reserpine-treated synaptosomes. Subsequently, both fractions were
centrifuged at 1000 x g for 1 mm, the supernatant was decanted, and
the synaptosomes were resuspended in fresh incubation buffer. The
effects of 100 M LHM and 1 tM R(-)-apomorphine were tested on
both fractions.
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a purification step with aluminum oxide by high pressure liquid chro- FIG. 1. Time courses of synaptosomal DOPA, DA, and DOPAC con-
matography and subsequent electrochemical detection (7). a-Methyl- tent
DOPA and adrenaline were used as internal standards for DOPA and Rat striatal synaptosomes were incubated at pH 7.2 and 37’ for
DA, respectively. Recovery of DOPAC was determined in separate various lengths of time. Experiments were started by addition of NSD
samples by addition of a known amount of DOPAC; the obtained 1055 (time point 0) and stopped by perchloric acid addition. After
recovery (.-50%) was used to correct the DOPAC measurements. centrifugation, catechols were determined in the supernatant fluid.
Drug comparisons were performed in the same tissue preparation to DOPA production, and DA and DOPAC content are indicated in A, B,
avoid problems with variations in synaptosomal activity on different and C, respectively. Each point represents the arithmetic mean ± SD
days. All tests were performed in triplicate and the arithmetic mean ± of three observations.
A
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Synaptosomal DA decreased during the incubation pe-
nod; obviously some of the DA was metabolized to DO-
PAC, as a corresponding increase in DOPAC was found
(Fig. 1, B and C).
The inhibition of synaptosomal DOPA production by
reserpine and LHM is shown in Fig. 2A. Reserpine is
known to induce a temporary block of DOPA production
by blocking DA uptake into vesicles, resulting in a tran-
sient increase in cytosolic DA, and ultimately, depletion
of vesicle stores of this amine. This is indicated by the
observed decrease in synaptosomal DA and its recovery
as DOPAC (Fig. 2, B and C). The transient increase in
free cytosolic DA will result in the inhibition of the
activity of TH, which is a cytosolic enzyme. LHM at
high concentrations seems to have a reserpine-like effect
on striatal synaptosomes as well. There was no effect of
LHM (up to 100 jzM) on soluble striatal TH (not shown).
To elucidate the mechanism of action of LHM on syn-
aptosomal DOPA production, the synaptosomes were
depleted of DA by preincubation with 10 M reserpine.
Fig. 3 shows that LHM was ineffective in DA-depleted
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FIG. 2. Effects of reserpine and LHM on syriaptosornal DOPA pro-
duction, and DA and DOPAC content
Synaptosomes were incubated with reserpine or LHM at various
concentrations for 20 mm. DOPA production, and DA and DOPA
content are indicated in A, B, and C, respectively. Each point represents
the arithmetic mean ± SD of three observations.
LHMApo Co LHM Apo
Co LHM Apo
reserpine-pretreat ment
FIG. 3. Effects oILHM and R(-)-apomorphine on DOPA production,
and DA and DOPAC content in DA-depleted synaptosomes
Synaptosomes were depleted of DA by pretreatment with 10 zM
reserpine. The effect of 100 tM LHM and 1 zM R(-)-apomorphine was
tested on untreated synaptosomes (left group of columns) and synap-
tosomes depleted of DA (right group of columns). DOPA production,
and DA and DOPAC content are indicated in A, B, and C, respectively.
Each point represents the arithmetic mean ± SD of three observations.
R(-)-Apomorphine is known to block DOPA produc-
tion in striatal synaptosomes. S(+)-Apomorphine, which
is a DA antagonist with low affinity for DA receptors
(10), was almost equally potent as the R(-)-enantiomer
in blocking the DOPA production in striatal synapto-
somes (Fig. 4A). IC50 values for inhibition of synaptoso-
mal DOPA production were 410 and 970 nM for the
R(-)- and S(+)-enantiomers, respectively. In a second
set of experiments, respective IC values of 630 and 950
nM were obtained. Synaptosomal DA and DOPAC did
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a Haloperidol concentrations.
FIG. 4. Inhthition of synaptosomal
DOPA production and TH activity by
R(-)- and S(+)-apomorphine
Rat striatal synaptosomes were incu-
bated at pH 7.2 and 37’ for 20 mm with
S(+)- or R(-)-apomorphine added at
various concentrations (A). Crude solu-
ble TH from rat striatum was incubated
at pH 7.2 and 37’ for 30 mm with 30 sM
tyrosine and 1 mM BR, with S(+)- or
R(-)-apomorphine added at various con-
centrations (B). Each point represents
the arithmetic mean ± SD of three ob-
servations.
S(+)-apomorphine when compared to untreated con-
trols.
When the effects of both enantiomers were tested in
soluble TH preparations, IC values for the inhibition
of TH were 470 and 890 nM for the R(-)- and the S(+)-
enantiomers, respectively (Fig. 4B). In a second set of
experiments, respective IC50 values of 420 and 890 nM
were obtained.
Table 1 shows the effect of haloperidol on the inhibi-
tion of DOPA production from striatal synaptosomes,
induced by the two enantiomers of apomorphine. In the
NSD 1055 assay, haloperidol had only marginal effects
on the R(-)-apomorphine-induced inhibition. Haloperi-
dol alone induced a small decrease in DOPA production;
simultaneously, the synaptosomal DA content was de-
creased to 82% and DOPAC content was increased to
113% as compared to the controls.
In the [3H]catechol assay, the effect of 1 M haloperi-
do! alone on DOPA production was much more pro-
nounced. Haloperidol at 1 iM yielded a slight decrease
in the R(-)-apomorphine-induced inhibition and a slight
increase in the S(+)-apomorphine-induced inhibition of
synaptosomal [3H]catechol production. At this haloper-
idol concentration, the assessment of the haloperidol-
induced reversal critically depended on the 100% value
used. At a concentration of 100 nM, haloperidol had only
marginal effects on DOPA production alone and on
apomorphine-induced inhibition; at 10 nM, haloperidol
was ineffective (not shown). Both apomorphine enanti-
omers are effective inhibitors of DOPA production in the
[3H]catechol assay as well (Table 1).
DISCUSSION
Hirata et al. (14) and Haycock and Patrick (15) re-
cently demonstrated that determination of DOPA accu-
mulation after blocking the aromatic L-amino acid de-
carboxylase can be used as an indirect measure of TH
activity in rat brain slices and synaptosomes. Our direct
measurements of catechols allow the assessment of syn-
aptosomal DA and DOPAC. Simultaneous monitoring of
these catechols easily detects drugs which deplete DA
from vesicular stores, resulting in a transient elevation
of cytosolic DA and a Consequent inhibition of synapto-
somal TH.
While the accumulation of DOPA may eventually lead
to a feedback inhibition of TH, the latter does not appear
to occur during the time course of the incubations. This
indicates that either not enough DOPA has accumulated
to inhibit the enzyme or DOPA is released into the
incubation buffer. From our experiments with cell cul-
tures we know that DOPA easily leaves the cells (7, 16).
Ip et al. (17) showed that considerable amounts of DOPA
are also released by rat superior ganglia if the aromatic
L-amino acid decarboxylase is blocked. Thus, determi-
nation of synaptosomal DOPA accumulation appears to
be a valid assay to measure TH activity in striatal
synaptosomes.
Our studies show that R(-)-apomorphine blocks
DOPA production in striatal synaptosomes with an IC50
of 410-630 flM. This value is in accordance with the
findings of other authors in striatal synaptosomes (5, 11,
18-22) and slices (4, 23-26). S(+)-Apomorphine, first
TABLE 1
Antagonism between haloperidol and the two apomorphine enantiomers regarding DOPA production ofstriatal synaptosomes
The results obtained with the NSD 1055 assay and with the [3H]catechol assay are shown. The data represent the arithmetic mean ± SD of
five determinations.
DOP A production (pm ol/mg protein . mm)
NSD 10 55 assay [3H]catechol assay















2.38 ± 0.12 3.66 ± 0.07
0.56 ± 0.07 0.46 ± 0.02
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tion.
synthesized by Saari and King (27), was found to be a
DA antagonist both in vivo and in vitro (9, 10, 28). If
inhibition of synaptosomal DOPA production by R(-)-
apomorphine, a D2-agonist (10), involves a dopaminergic
receptor, then S(+)-apomorphine, a D2-antagonist (10),
should be unable to inhibit synaptosomal DOPA produc-
tion and should be able to reverse the effect of R(-)-
apomorphine. The observations concerning the autore-
ceptor regulation of DA release are in accordance with
this idea: Lehmann et al. (28) observed no effect of S(+)-
apomorphine on electrically evoked release of DA from
striatal slices, and S(+)-apomorphine was able to antag-
onize the R(-)-apomorphine-induced effect.
In contrast to these results on dopaminergic regulation
of DA release, S(+)-apomorphine was an effective
blocker of synaptosomal DOPA synthesis (Fig. 4). These
findings indicate that inhibition of synaptosomal DOPA
production by R(-)-apomorphine may be explained by
its direct inhibitory effect on TH. Goldstein et al. (4)
reported in 1970 that, due to its catechol structure, R(-)-
apomorphine is a direct blocker of soluble striatal TH.
Whereas IC50 values above 10 tM were determined (4,
18, 20), we recently showed that the inhibitory potency
of R(-)-apomorphine on soluble TH critically depended
on the incubation conditions used; at pH 7.2 and with
the natural cofactor BH4, the IC was 200-600 nM,
depending on the cofactor concentration used (8).
Recently, Shen et al. (29) reported that R(-)-apomor-
phine and other catechols can block the dihydropteridine
reductase (EC 1.6.99.10). The relevance of this finding
for the inhibition of DOPA production remains to be
established. We demonstrated blockade of DOPA pro-
duction by R(-)-apomorphine (ICro < 1 tiM) in cell
cultures with no changes of cellular BH4 content (16).
Moreover, R(-)-apomorphine (10 mg/kg, intraperitone-
ally) did not affect striatal BH4 content in rats.3 The
effects of the apomorphine enantiomers on TH activity
in our assay system must have been direct. Even if all
tyrosine (30 tiM) in the assay system were converted to
DOPA, this would hardly change the BH4 concentration
(1 mM). In accordance with this consideration, omission
of dihydropteridine reductase did not affect the IC of
R(-)-apomorphine (data not shown).
It has been pointed out by Waggoner et al. (20) that
efficient blockade of DOPA production in vitro is ob-
tamed only by DA agonists with catechol structure. Non-
catechols like ergots and pergolide (19, 22, 26) showed
only weak or no effects on DOPA production in vitro.
Moreover, several groups (30-32) showed that DA ago-
nists like 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydro-
naphthalene or DA, which are subject to the DA uptake
system, lose their inhibitory effects on synaptosomal
DOPA production, if their uptake into the synaptosomes
is prevented. From these observations, Cerrito and Rai-
ten (30) and Maura and Raiteri (31) suggested that it is
the DA newly taken up that regulates DOPA synthesis
in striatal nerve endings.
In contrast, Waggoner et al. (20) and Tissari et al. (11)
showed that 7-hydroxy-N,N-di-n-propyl aminotetralin
3 M. Br#{228}utigam, B. Kittner, and H. Herken, unpublished observa-
and LHM (both without catechol structure) have a par-
tial inhibitory effect on synaptosomal DOPA production.
In contrast to R(-)-apomorphine, both drugs exhibited
a rather flat dose-response curve, and high concentra-
tions (100 mM) caused only 50% maximal inhibition of
DOPA production. We only examined LHM, and our
data indicate that the effect of LHM on synaptosomal
DOPA production can be explained by a reserpine-like
mechanism, i.e., via depleting DA from its vesicular
stores into the cytoplasm (Fig. 2). In accordance with
this hypothesis, LHM-but not R(-)-apomorphine-
loses its effect on DOPA production in DA-depleted
synaptosomes (Fig. 3). The effects of reserpine (or lis-
uride) on DOPA production are transient: if there exists
no DA which can be released, DOPA production will
once more increase. This is indicated by the restored
level of DOPA production after pretreatment with reser-
pine (controls, Fig. 3).
In support of a receptor-mediated regulation of DA
biosynthesis in vitro, many authors reported a reversal
of the apomorphine-induced inhibition of synaptosomal
DOPA production by neuroleptics. However, this rever-
sal was only weak and was not observed by others (4, 19,
20). In the NSD 1055 assay, we only observed a marginal
antagonism between R(-)-apomorphine and haloperidol
(1 M) (see Table 1). In the [3Hjcatechol assay, the
antagonism seemed to be more pronounced, especially if
the effect of R(-)-apomorphine in the presence of halo-
peridol was assessed by comparison with the value ob-
tamed by incubation with haloperidol alone (e.g., Ref.
18). If this procedure for calculating the antagonism
between haloperidol and apomorphine is chosen, there
also exists an antagonism between S(+)-apomorphine
and haloperidol at a concentration of 1 M. With halo-
peridol at a concentration of 100 nM, the antagonism
leveled off and was no longer detected at a concentration
of 10 nM.
Whether this marginal reversal of the R(-)-apomor-
phine-induced inhibition of DOPA production by halo-
peridol at high concentrations suffices to assume an
autoreceptor-mediated control of DOPA synthesis in this
model may remain to be discussed. Comparing the results
obtained in vitro on the regulation of DA synthesis and
DA release, the evidence for a common mechanism seems
to be rather weak: R(-)-apomorphine blocked electrically
evoked DA release in striatal slices with an IC50 well
below 100 nM; ergots and pergolide also were effective
blockers of DA release; different classes of neuroleptics
facilitated DA release (at nanomolar concentrations) and
completely reversed the inhibition by DA agonists (for
reviews see Refs. 33 and 34).
Recently, Compton and Johnson (35) and Fowler et al.
(36) suggested that an autoreceptor control of synapto-
somal TH activity cannot be established in vitro. There-
fore, it may be worthwhile to reconsider the validity of
this model for testing drugs with respect to their DA
autoreceptor-stimulating or -blocking activities.
Haloperidol at a concentration of 1 iM caused a pro-
nounced inhibition of TH in the [3H]catechol assay,
which was in accordance with the findings of others (e.g.,
Refs. 5 and 18). Delanoy and Dunn (24) suggested that
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this inhibition was due to a reserpine-like effect if halo-
peridol was applied at high concentrations. The direct
measurement of a decrease in DA and an increase in
DOPAC in the NSD 1055 assay supported this concept,
although the observed blockade of DOPA production was
lower in the NSD 1055 assay, and other unknown mech-
anisms possibly contributed to the apparent decrease of
[3H]catechol production. Since, in the [3Hjcatechol as-
say, the production of all catechols was measured (i.e.,
besides that of DOPA, at least also that of DA and
DOPAC), haloperidol might interfere with the synthesis
of one of the latter products. Conversely, haloperidol
may interfere with the transport of labeled tyrosine into
the synaptosomes.
Our studies allow the following conclusions. 1) If there
exists an autoreceptor-mediated regulation of DA syn-
thesis, a reliable method for its demonstration in vitro
remains to be established. 2) DA agonists with catechol
structure are apparently not good tools for this purpose
because of a pronounced direct effect on TH. Comparison
of both apomorphine enantiomers may distinguish direct
from receptor-mediated effects on TH. 3) Simultaneous
measurement of synaptosomal DA and DOPAC may
reveal indirect drug actions, as demonstrated for LHM.
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